Co-relation of Overall Survival with Peripheral Blood-based Inflammatory Biomarkers in Advanced Stage Non-small Cell Lung Cancer Treated with Anti-programmed Cell Death-1 Therapy: Results from a Single Institutional Database

Overview

Journal Acta Oncol

Specialty Oncology

Date 2017 Dec 16

PMID 29241410

Citations 24

Authors

Abdul Rafeh Naqash

Chipman Robert Geoffrey Stroud

Muhammad Umer Butt

Grace K Dy

Aparna Hegde

Mahvish Muzaffar

Li V Yang

Maida Hafiz

Cynthia R Cherry

Paul R Walker

Affiliations

Soon will be listed here.

Citing Articles

Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis.

Wu J, Wang H, Yang R, Liu D, Li W Front Oncol. 2024; 14:1449853.

PMID: 39464717 PMC: 11502296. DOI: 10.3389/fonc.2024.1449853.

The relationship between clinicopathological variables, systemic inflammation, and CT-derived body composition with survival in patients with advanced non-small cell lung cancer receiving nivolumab as a second-line treatment.

Saeed R, McGovern J, Bench H, Dolan R, McMillan D, Cascales A Cancer Med. 2023; 12(24):22062-22070.

PMID: 38088761 PMC: 10757089. DOI: 10.1002/cam4.6805.

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.

Naqash A, McCallen J, Mi E, Iivanainen S, Marie M, Gramenitskaya D J Immunother Cancer. 2023; 11(10).

PMID: 37852738 PMC: 10603340. DOI: 10.1136/jitc-2023-007310.

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50.

Takahara Y, Abe R, Sumito N, Tanaka T, Ishige Y, Shionoya I Thorac Cancer. 2023; 14(27):2754-2760.

PMID: 37536667 PMC: 10518233. DOI: 10.1111/1759-7714.15059.

Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.

Xu Y, Ma K, Zhang F, Ma M, Hong L, Wang J Exp Ther Med. 2023; 26(2):361.

PMID: 37408861 PMC: 10318603. DOI: 10.3892/etm.2023.12060.

References

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View

Canna K, McArdle P, McMillan D, McNicol A, Smith G, McKee R . The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005; 92(4):651-4. PMC: 2361875. DOI: 10.1038/sj.bjc.6602419. View

Maleki Vareki S, Garrigos C, Duran I . Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017; 116:116-124. DOI: 10.1016/j.critrevonc.2017.06.001. View

Gupta D, Lis C . Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010; 9:69. PMC: 3019132. DOI: 10.1186/1475-2891-9-69. View

Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P . Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017; 58:1-13. DOI: 10.1016/j.ctrv.2017.05.005. View

Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

Coffelt S, Wellenstein M, de Visser K . Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016; 16(7):431-46. DOI: 10.1038/nrc.2016.52. View

Ferrucci P, Gandini S, Battaglia A, Alfieri S, Di Giacomo A, Giannarelli D . Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015; 112(12):1904-10. PMC: 4580390. DOI: 10.1038/bjc.2015.180. View

Muller I, Munder M, Kropf P, Hansch G . Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. Trends Immunol. 2009; 30(11):522-30. DOI: 10.1016/j.it.2009.07.007. View

10.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

11.

Grigg C, Rizvi N . PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. J Immunother Cancer. 2016; 4:48. PMC: 4986262. DOI: 10.1186/s40425-016-0153-x. View

12.

Lang T . Documenting research in scientific articles: Guidelines for authors: 3. Reporting multivariate analyses. Chest. 2007; 131(2):628-32. DOI: 10.1378/chest.06-2088. View

13.

Rafei H, El-Bahesh E, Finianos A, Nassereddine S, Tabbara I . Immune-based Therapies for Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(2):377-387. DOI: 10.21873/anticanres.11330. View

14.

Simmons C, Koinis F, Fallon M, Fearon K, Bowden J, Solheim T . Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors. Lung Cancer. 2015; 88(3):304-9. DOI: 10.1016/j.lungcan.2015.03.020. View

15.

Simeone E, Gentilcore G, Giannarelli D, Grimaldi A, Caraco C, Curvietto M . Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014; 63(7):675-83. PMC: 11028686. DOI: 10.1007/s00262-014-1545-8. View

16.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

17.

Laird B, Kaasa S, McMillan D, Fallon M, Hjermstad M, Fayers P . Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013; 19(19):5456-64. DOI: 10.1158/1078-0432.CCR-13-1066. View

18.

Shalapour S, Karin M . Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015; 125(9):3347-55. PMC: 4588298. DOI: 10.1172/JCI80007. View

19.

Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139-148. DOI: 10.1016/j.ejca.2015.11.016. View

20.

Budczies J, Klauschen F, Sinn B, Gyorffy B, Schmitt W, Darb-Esfahani S . Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7(12):e51862. PMC: 3522617. DOI: 10.1371/journal.pone.0051862. View